[1]Jun-Xiang,Zhang,Da-Qiang,等.P21-activated kinase 1 and breast cancer[J].中华乳腺病杂志(电子版),2010,4(5):544-553.
点击复制

P21-activated kinase 1 and breast cancer()

中华乳腺病杂志（电子版）[ISSN:1674-0807/CN:11-9146/R]

卷:
第4卷
期数:
2010年5期
页码:
544-553
栏目:
综述
出版日期:
2010-10-01

文章信息/Info

作者:
Jun-Xiang;Zhang;Da-Qiang;Li;Rakesh;Kumar
Department of Biochemistry and Molecular Biology, The George Washington University Medical Center, Washington, DC 20037, USA
关键词:
Breast neoplasms;  P21-activated kinase 1
摘要:
The p21activated kinase 1 (PAK1) belongs to PAKs family, a group of highly evolutionarily conserved protein family of serine/threonine kinases, which acts as a downstream effector of the small GTPases Cdc42 and Rac1, firstly reported in 1994. As a serine/threonine kinase, PAK1 plays an important role in many cellular functions including cell morphogenesis, motility, survival, mitosis, angiogenesis, and tumorigenesis. More than 40 proteins have been reported to be phosphorylated by PAK1. Accumulating experimental data in multiple experimental systems provide compelling evidence that PAK1 plays an important role in breast cancer promotion and progression. PAK1 is overexpressed and/or hyperactivated in more than 50% of breast cancers. On the other hand, PAK1 overexpression in estrogen receptoralpha (ER-α) positive breast cancer is also closely associated with a reduced responsiveness to tamoxifen therapy. Since PAK1 plays such a vital role in breast cancer, PAK1targeted therapeutic approaches are likely to be useful in breast cancer treatment as well as in other human cancers with PAK1 upregulation and/or hyperactivation.

相似文献/References:

[1]Per,Eystein,Lnning.Role of molecular markers in breast cancer therapy[J].中华乳腺病杂志(电子版),2010,4(5):479.
[2]Louis,Wing-Cheong,Chow,等.Potential of a COX2 inhibitor in lowering chemotherapyinduced neutropenia[J].中华乳腺病杂志(电子版),2010,4(5):496.
[3]Kentaro,Tamaki,Hironobu,等.An analysis of vascularity and neovascularization in surgical pathology materials of breast carcinoma and its clinical significance[J].中华乳腺病杂志(电子版),2010,4(5):521.
[4]Adrian,YS,Yip,等.Methods of early detection: would clinical breast examination and breast ultrasonography be a good alternative to mammography?[J].中华乳腺病杂志(电子版),2011,5(6):646.
[5]Kentaro,Tamaki,Hironobu,等.New development of breast cancer histological evaluation related to determination of therapeutic option for the patients[J].中华乳腺病杂志(电子版),2011,5(6):721.
[6]Wings,T.,Y.,等.Application of single and combination therapy of clarithromycin and tamoxifen to suppress breast cancer cell proliferation and metabolism[J].中华乳腺病杂志(电子版),2012,6(1):45.
[7]Satoko,Suzuki,Miki,等.Efficacy of volume navigation in assessment of extent of breast cancer[J].中华乳腺病杂志(电子版),2012,6(5):533.
[8]Chong,Le,等.Is it necessary to do axillary dissection in old women with breast cancer? A meta-analysis of randomized clinical trials[J].中华乳腺病杂志(电子版),2012,6(6):622.
[9]TANG,Qi,等.Giant phyllodes tumor in both breasts:one case report and literature review[J].中华乳腺病杂志(电子版),2013,7(2):142.
[10]Louis Wing Cheong Chow,Wings Tjing Yung Loo,Qing Liu. Individualized therapy for breast cancer:a decade of improvement[J].中华乳腺病杂志(电子版),2015,9(4):223.
　[J].Chinese Journal of Breast Disease (Electronic Version),2015,9(5):223.

更新日期/Last Update: 2010-01-20